Medera And Novoheart Collaborate With Physician-Scientists At University Of California San Diego School Of Medicine And Mayo Clinic To Develop Mini-Heart Models Aimed At Transforming Treatment For HLHS

Benzinga·06/24/2025 12:10:29

Listen to the news

First-ever mini-Heart models will be created from hypoplastic left heart syndrome (HLHS) patient stem cells, enabling personalized insights into their causes and treatments
Partnership aims to improve survival and quality of life for pediatric HLHS patients by developing new tools that can identify which children will potentially benefit most from surgery, transplantation, or novel therapies
Leveraging Novoheart's proprietary mini-Heart Platform, this partnership aligns with emerging FDA guidelines supporting human-relevant, animal-free drug development

BOSTON and SAN DIEGO and ROCHESTER, Minn., June 24, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, and Novoheart, its wholly owned pre-clinical subsidiary pioneering human-based cardiac tissue engineering for disease modelling and drug screening, today announced a groundbreaking collaboration with physician-scientists at the University of California San Diego School of Medicine and Mayo Clinic. The goal of the partnership is to develop the first human mini-heart models of hypoplastic left heart syndrome (HLHS) using stem cells from real patients and improve the understanding of this disease with the goal of developing more personalized treatment strategies for children born with this devastating condition.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
① During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit: https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English